Literature DB >> 11024346

The study of cell-mediated immune response in recurrent vulvovaginal candidiasis.

U Nawrot1, K Grzybek-Hryncewicz, U Zielska, A Czarny, J Podwińska.   

Abstract

The aim of this work was to examine in vitro the ability of cells from patients with recurrent vulvovaginal candidiasis (RVVC) to cell-mediated immune response. Peripheral blood mononuclear cells (PBMC) and whole blood cells (WBC) of 37 RVVC patients in acute infection and 14 in remission were examined for the ability to proliferation and cytokines production (IFN, TNF, IL-6). As a control, a group of 25 healthy women were examined. The cells were stimulated with Candida antigen (HKCA), LPS and PHA. To indicate the level of cytokines, the following cell-lines were used: A549 for IFN, WEHI 164 for TNF and 7TD1 for IL-6. The proliferation/death of cells was determined by colorimetric test using MTT. Distinct suppression of cell-mediated immune response (CMI) was shown in all patients comparing to the control. Greatest suppression was found in the acute phase of the disease. The ability of cells to proliferate and produce IFN increases only in remission. The data seem to suggest that in this phase of disease, the ability of cell-mediated immune response is restored. It was also indicated that IFN may take part in protection against Candida infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11024346     DOI: 10.1111/j.1574-695X.2000.tb01509.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  8 in total

1.  Increased susceptibility of secretor factor gene Fut2-null mice to experimental vaginal candidiasis.

Authors:  Elizabeth A Hurd; Steven E Domino
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

2.  Genetic basis for recurrent vulvo-vaginal candidiasis.

Authors:  Martin Jaeger; Theo S Plantinga; Leo A B Joosten; Bart-Jan Kullberg; Mihai G Netea
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

3.  Prospects for development of a vaccine to prevent and control vaginal candidiasis.

Authors:  Paul L Fidel; Jim E Cutler
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

4.  Cervical mucins carry alpha(1,2)fucosylated glycans that partly protect from experimental vaginal candidiasis.

Authors:  Steven E Domino; Elizabeth A Hurd; Kristina A Thomsson; David M Karnak; Jessica M Holmén Larsson; Elisabeth Thomsson; Malin Bäckström; Gunnar C Hansson
Journal:  Glycoconj J       Date:  2009-12       Impact factor: 2.916

5.  Immune Regulation and Its Role in the Pathogenesis of Candida Vaginitis.

Authors:  Paul L. Fidel
Journal:  Curr Infect Dis Rep       Date:  2003-12       Impact factor: 3.725

6.  Gene polymorphisms in pattern recognition receptors and susceptibility to idiopathic recurrent vulvovaginal candidiasis.

Authors:  Diana C Rosentul; Corine E Delsing; Martin Jaeger; Theo S Plantinga; Marije Oosting; Irene Costantini; Hanka Venselaar; Leo A B Joosten; Jos W M van der Meer; Bertrand Dupont; Bart-Jan Kullberg; Jack D Sobel; Mihai G Netea
Journal:  Front Microbiol       Date:  2014-09-23       Impact factor: 5.640

Review 7.  Immunopathology of Recurrent Vulvovaginal Infections: New Aspects and Research Directions.

Authors:  Namarta Kalia; Jatinder Singh; Manpreet Kaur
Journal:  Front Immunol       Date:  2019-08-28       Impact factor: 7.561

8.  Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen?

Authors:  Zahra Talaei; Saba Sheikhbahaei; Vajihe Ostadi; Mazdak Ganjalikhani Hakemi; Mohsen Meidani; Elham Naghshineh; Majid Yaran; Alireza Emami Naeini; Roya Sherkat
Journal:  Int J Fertil Steril       Date:  2017-08-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.